A new development of matrix metalloproteinase inhibitors: Twin hydroxamic acids as potent inhibitors of MMPs

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 9, 2005, Pages 2311-2314

  Rossello, Armando ^a   Nuti, Elisa ^a   Catalani, Maria Pia ^a   Carelli, Paolo ^a   Orlandini, Elisabetta ^a   Rapposelli, Simona ^a   Tuccinardi, Tiziano ^a   Atkinson, Susan J ^b   Murphy, Gillian ^b   Balsamo, Aldo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antiangiogenic agents; Arylsulfonamido based hydroxamate; MMP 2 MT1 MMP selective inhibitors; MMP inhibitors; MMPi; Twin hydroxamic acids

Indexed keywords

BENZYL 4 (HYDROXYAMINO) 3 [ISOPROPOXY(1,1' BIPHENYL 4 YLSULFONYL)AMINO] 4 OXOBUTYLCARBAMATE; CARBAMIC ACID DERIVATIVE; DIMER; GELATINASE A; GELATINASE B; HYDROXAMIC ACID; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MONOMER; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

EID: 20244383477     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.03.002     Document Type: Article

References (37)

1. M. Seiki, and I. Yana Cancer Sci. 94 2003 569
2. A.R. Folguera, A.M. Pendas, L.M. Sanchez, and C. Lopez-Otin Int. J. Dev. Biol. 48 2004 411
3. A.H. Baker, D.R. Edwards, and G. Murphy J. Cell Sci. 115 2002 3719
4. G. Murphy, and T. Crabbe Methods Enzymol. 248 1995 470
5. D.E. Kleiner, and W.G. Stetler-Stevenson Cancer Chemother. Pharmacol. 43 1999 S42
6. R.T. Aimes, and J.Q. Quigley J. Biol. Chem. 270 1995 5872
7. T. Itoh, M. Tanioka, H. Matsuda, H. Nishimoto, T. Yoshioka, R. Suzuki, and M. Uehira Clin. Exp. Metastasis 17 1999 177
8. M.A. Lafleur, P.A. Forsyth, S.J. Atkinson, G. Murphy, and D.R. Edwards Biochem. Biophys. Res. Commun. 282 2001 463
9. K.N. Cowan, P.L. Jones, and M. Rabinovitch Circ. Res. 84 1999 1223
10. P.L. Jones, J. Crack, and M. Rabinovitch J. Cell Biol. 1997 279
11. P.J. Eguchi, G.D. Dempsey, G.D. Frank, D. Motley, and T. Inagami J. Biol. Chem. 276 2001 7957
12. M. Ahonen, M. Poukkula, A.H. Baker, M. Kashiwagi, H. Nagase, J.E. Eriksson, and V.-M. Kähäri Oncogene 22 2003 2121
13. G. Giannelli, and S. Antonaci Histol. Histopath. 17 2002 339
14. A. John, and G. Tuszynski Pathol. Oncol. Res. 7 2001 14
15. L.M. Coussens, B. Fingleton, and L. Matrisian Science 295 2002 2387
16. N. Borkakoti Biochem. Soc. Trans. 32 2004 17 19
17. J.W. Hutchinson, G.M. Tierney, S.L. Parson, and T.R.C. Davis J. Bone Joint Surgery 80 1998 907
18. K. Holmbeck, P. Bianco, J. Caterina, S. Yamada, M. Kromer, S.A. Kuznetsov, M. Mankani, P.G. Robey, A.R. Poole, I. Pidoux, J.M. Ward, and H. Birkedal-Hansen Cell 99 1999 81
19. W.P. Steward Cancer. Chemother. Pharmacol. 43 1999 S56
20. L. Dahlberg, R.C. Billinghurst, P. Manner, F. Nelson, G. Webb, M. Ionescu, A. Reiner, M. Tanzer, D. Zukor, J. Chen, H.E. Van Wart, and A.R. Poole Arthritis Rheum. 43 2000 673
21. R. Scatena Exp. Opin. Invest. Drugs 9 2000 2159
22. A. Scozzafava, T. Owa, A. Mastrolorenzo, and C.T. Supuran Curr. Med. Chem. 10 2003 925
23. C.K. Wada, J.H. Holms, M.L. Curtin, Y. Dai, A.S. FlorJancic, R.B. Garland, Y. Guo, H.R. Heyman, J.R. Stacey, D.H. Steinman, D.H. Albert, J.J. Bouska, I.N. Elmore, C.L. Goodfellow, P.A. Marcotte, P. Tapang, D.W. Morgan, M.R. Michaelides, and S.K. Davidsen J. Med. Chem. 45 2002 219
24. C.T. Supuran, A. Casini, and A. Scozzafava Med. Res. Rev. 23 2003 535
25. Zook, S. E.; Dagnino, R., Jr.; Deason, M. E.; Bender, S. L.; Melnick, M. J. WO Patent 97/20824; 1997, 127, 108945. Chem. Abstr. 1995, 123, 2870
26. C.T. Supuran, and A. Scozzafava H.J. Smith C. Simons Proteinase and Peptidase Inhibitors: Recent Potential Targets for Drug Development 2002 Taylor & Francis London & New York 35 61
27. M.M. Bernardo, S. Brown, Z.-H. Li, R. Fridman, and S. Mobashery J. Biol. Chem. 277 2002 11201
28. S.A. Rabbani, P. Harakidas, Y. Guo, D. Steinman, S.K. Davidsen, and D.W. Morgan Int. J. Cancer 87 2000 276
29. O. Nyormoi, L. Mills, and M. Bar-Eli Cell Death Differ. 5 2003 558
30. A. Rossello, E. Nuti, E. Orlandini, P. Carelli, S. Rapposelli, M. Macchia, F. Minutolo, L. Carbonaro, A. Albini, R. Benelli, G. Cercignani, G. Murphy, and A. Balsamo Bioorg. Med. Chem. 12 2004 2441
31. A. Rossello, E. Nuti, P. Carelli, E. Orlandini, M. Macchia, S. Nencetti, M. Zandomeneghi, F. Balzano, G. Uccello-Barretta, A. Albini, R. Benelli, G. Cercignani, G. Murphy, and A. Balsamo Bioorg. Med. Chem. Lett. 15 2005 1327
32. Unpublished results from our laboratory
33. J.-M. Contreras, and J.-J. Bourguignon Identical and Non-Identical Twin Drugs C.G. Wermuth The Practice of Medicinal Chemistry 2nd ed. 2004 Academic (An imprint of Elsevier) London 251 273
34. D.H. Hua, M. Tamura, M. Egi, K. Werbovetz, D. Delfin, M. Salem, and P.K. Chiang Bioorg. Med. Chem. 11 2003 4357
35. P.G. Parson, C. Hansen, D.P. Fairlie, M.L. West, P.A.C. Danoy, R.A. Sturm, I.S. Dunn, J. Pedley, and E.M. Ablett Biochem. Pharmacol. 53 1997 1719
36. R. Breslow, B. Jursic, Z.F. Yan, E. Friedman, L. Leng, L. Ngo, R.A. Rifkind, and P.A. Marks Proc. Natl. Acad. Sci. U.S.A. 88 1991 5542
37. 5 cells/well in selection medium and incubated at 37°C overnight. The following day, cells were washed twice to remove serum and then incubated in 300 μL/well DMEM with insulin, transferrin and selenium supplements (Sigma, UK) added. Test compounds ((R,R)-2b, (R)-1) at 0, 1, 5 and 10 μM were added to duplicate wells. After a further 24 h, media were removed for zymographic analysis and the cells were washed in PBS. The cells from each well were harvested by trypsinization, resuspended in PBS and mixed 1:1 with trypan blue (0.4% w/v, Sigma, UK). After 5 min, a sample of cell suspension from each well was removed and introduced into a haemocytometer. The total number of cells in the upper grid was counted and a separate count was taken of the cells, which had taken up the blue dye, that is, the dead cells. The process was repeated by counting the cells in the lower grid. Percentage toxicity for each compound at the different concentrations was calculated as a mean of the values for duplicate wells, after subtracting the values for the wells without either compound